Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Eur J Dermatol ; 21(4): 568-72, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21697032

RESUMEN

The combination of etanercept, a tumour necrosis factor α inhibitor, with narrow-band ultraviolet B (NB-UVB) phototherapy has recently been reported to be effective in moderate-to-severe plaque psoriasis, yielding better results than either monotherapy. To assess the efficacy and safety of this combined treatment using the lower approved etanercept dosage. In this single-arm open-label study patients received etanercept 50 mg once weekly combined with NB-UVB phototherapy three times weekly for 8 weeks, followed by etanercept alone until week 12. We evaluated the proportion of patients achieving 75%, 90% and 100% improvement of their initial PASI score (PASI75, PASI90, and PASI100, respectively). Patients were 19 men and 14 women, mean age 48.3 years ± 12.1 standard deviation (SD) and mean baseline Psoriasis Area and Severity Index (PASI) score 22.5 ± 7.5. On treatment weeks 4, 8, and 12, 24.2%, 66.7%, and 81.8% of patients achieved PASI75; 8.0%, 15.1%, and 57.6% reached PASI90, and 0%, 6.0%, and 24.2% attained PASI100, respectively. There were no severe side effects. Low-dosage etanercept combined with NB-UVB phototherapy is an effective, safe and economical approach to treat moderate-to-severe plaque psoriasis. Further studies are clearly required to assess its long-term efficacy and safety.


Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Inmunoglobulina G/uso terapéutico , Psoriasis/terapia , Receptores del Factor de Necrosis Tumoral/uso terapéutico , Terapia Ultravioleta/métodos , Antiinflamatorios no Esteroideos/administración & dosificación , Enfermedad Crónica , Terapia Combinada , Etanercept , Femenino , Humanos , Inmunoglobulina G/administración & dosificación , Masculino , Persona de Mediana Edad , Calidad de Vida , Receptores del Factor de Necrosis Tumoral/administración & dosificación , Resultado del Tratamiento
2.
J Am Acad Dermatol ; 57(4): 665-8, 2007 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17870431

RESUMEN

Porokeratosis of Mibelli is a disorder of epidermal keratinization characterized by annular plaques with an atrophic center surrounded by a keratotic wall. We report a case of a giant verrucous porokeratosis of Mibelli mimicking psoriasis that developed in a patient with psoriasis and therefore went unrecognized for a long time. Histologically the lesion combined features of porokeratosis at the periphery and of psoriasis at its center, a picture recently described as "psoriasis encircled by porokeratosis." The possible pathogenetic relationship between psoriasis and the development of porokeratosis is also discussed.


Asunto(s)
Errores Diagnósticos , Poroqueratosis/diagnóstico , Psoriasis/diagnóstico , Anciano , Diagnóstico Diferencial , Femenino , Humanos , Poroqueratosis/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA